Home › NCT07843264

PPI Dosing Per CYP2C19 Genotype

A Pilot Study to Assess Healing of Erosive Esophagitis in Patients Randomized to Conventional PPI Doses Versus Dosing Based on CYP2C19 Genotype

Who can join

Ages 18 to 90 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* age ≥ 18 years
* diagnosis of Gastroesophageal Reflux Disease (GERD) scheduled for an esophagogastroduodenoscopy (EGD)
* patients diagnosed with Erosive Esophagitis on endoscopy (EGD).

Exclusion Criteria:

* age \<18 years
* diagnosed with non-erosive reflux disease (NERD)
* pregnancy

About the study

This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.

What is being tested

• CYP2C19 based dosing Proton Pump Inhibitors (drug)
• Conventional proton pump inhibitor dose (drug)

Sponsor: University of Florida · Participants: 200 · Started: Nov 1, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07843264

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.